Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
1 clinical trials · Condition
◉ Watch Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer (NCT06254066) | Zhejiang Cancer Hospital | 2024-04-16 |
Track Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.